SPRC unveils quantum computing-enabled 3D protein modeling for AI drug discovery

Rhea-AI Filing Summary

SciSparc Ltd. disclosed the launch of an innovative quantum computing-enabled 3D protein modeling initiative intended to support AI-driven drug discovery. The report cites the program name and presents a company signature by Oz Adler as Chief Executive Officer and Chief Financial Officer on September 25, 2025. The filing attaches standard registration statement references but contains no financial results, funding details, partner names, timelines, or measurable milestones. This limits the ability to assess near-term commercial or revenue impact.

Positive

• Declared strategic focus on quantum computing-enabled 3D protein modeling to support AI drug discovery
• Senior management endorsement with CEO/CFO signature on September 25, 2025

Negative

• No disclosed funding or budget for the initiative, preventing assessment of scale
• No partners, milestones, or timelines were provided, limiting evaluation of near-term impact
• No financial or operational metrics in the filing to show expected outcomes or commercialization path

Insights

Biotech AI Strategist

Company announces a strategic R&D initiative combining quantum computing and 3D protein modeling.

The initiative signals a strategic pivot to apply quantum computing techniques to 3D protein modeling aimed at accelerating AI drug discovery workflows. If executed, this could enhance computational accuracy for molecular structures, which is a meaningful technical capability for discovery-stage operations.

The announcement lacks any budget, partners, timelines, or validation, creating execution and funding risk. Watch for updates specifying collaborators, pilot results, and a development timetable within the next 6–18 months to judge material impact.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025 (Report No. 3)

Commission file number: 001-38041

SCISPARC LTD.

(Translation of registrant’s name into English)

20 Raul Wallenberg Street, Tower A

Tel Aviv 6971916, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

CONTENTS

Changes in Management

On September 21, 2025, the board of directors (the “Board”) of SciSparc Ltd., (the “Company”) resolved to appoint Mr. Amitay Weiss, the former chairman of the Board, as the President of the Company and Mr. Itschak Shrem, the former President of the Company, as the chairman of the Board, effective immediately.

Press Release

On September 25, 2025, the Company issued a press release titled “SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery.” A copy of this press release is furnished herewith as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K and is incorporated by reference herein.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-286099, 333-275305, 333-269839, 333-266047, 333-248670 and 333-255408) and on Form S-8 (File Nos. 333-278437, 333-225773 and 333-286791) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

- 1 -

EXHIBIT INDEX

Exhibit No.
99.1		Press release issued by SciSparc Ltd. titled “SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery.”

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SciSparc Ltd.
Date: September 25, 2025	By:	/s/ Oz Adler
	Name:	Oz Adler
	Title:	Chief Executive Officer and Chief Financial Officer

- 3 -

FAQ

What did SciSparc (SPRC) announce in this 6-K filing?

SciSparc announced the launch of a quantum computing-enabled 3D protein modeling initiative to support AI drug discovery, signed by Oz Adler on September 25, 2025.

Does the filing include funding or budget details for the initiative?

No. The filing provides no information on budget, funding sources, or capital allocation for the program.

Are there any partners or collaborators named for the initiative?

No partners or collaborators are named in the disclosed text.

Does the filing state expected timelines or milestones?

No timelines or milestones are included; the filing does not specify pilot dates or development phases.

Will this filing affect SciSparc's reported financials?

Not immediately. The filing contains no earnings, revenue, or expense details tied to the initiative.